Stereotactic radiosurgery in the treatment of parasellar meningiomas: long-term volumetric evaluation

Or Cohen-Inbar, MD, PhD,1,4 Athreya Tata, BA,1 Shayan Moosa, MD,1 Cheng-chia Lee, MD,2,3 and Jason P. Sheehan, MD, PhD1

1Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia; 2Neurological Institute, Taipei Veterans General Hospital; 3National Yang-Ming University, Taipei, Taiwan; and 4Department of Neurosurgery, Rambam Maimonides Health Care Campus, Haifa, Israel

OBJECTIVE Parasellar meningiomas tend to invade the suprasellar, cavernous sinus, and petroclival regions, encroaching on adjacent neurovascular structures. As such, they prove difficult to safely and completely resect. Stereotactic radiosurgery (SRS) has played a central role in the treatment of parasellar meningiomas. Evaluation of tumor control rates at this location using simplified single-dimension measurements may prove misleading. The authors report the influence of SRS treatment parameters and the timing and volumetric changes of benign WHO Grade I parasellar meningiomas after SRS on long-term outcome.

METHODS Patients with WHO Grade I parasellar meningiomas treated with single-session SRS and a minimum of 6 months of follow-up were selected. A total of 189 patients (22.2% males, n = 42) form the cohort. The median patient age was 54 years (range 19–88 years). SRS was performed as a primary upfront treatment for 44.4% (n = 84) of patients. Most (41.8%, n = 79) patients had undergone 1 resection prior to SRS. The median tumor volume at the time of SRS was 5.6 cm³ (0.2–54.8 cm³). The median margin dose was 14 Gy (range 5–35 Gy). The volumes of the parasellar meningioma were determined on follow-up scans, computed by segmenting the meningioma on a slice-by-slice basis with numerical integration using the trapezoidal rule.

RESULTS The median follow-up was 71 months (range 6–298 months). Tumor volume control was achieved in 91.5% (n = 173). Tumor progression was documented in 8.5% (n = 16), equally divided among infield recurrences (4.2%, n = 8) and out-of-field recurrences (4.2%, n = 8). Post-SRS, new or worsening CN deficits were observed in 54 instances, of which 19 involved trigeminal nerve dysfunction and were 18 related to optic nerve dysfunction. Of these, 90.7% (n = 49) were due to tumor progression and only 9.3% (n = 5) were attributable to SRS. Overall, this translates to a 2.64% (n = 5/189) incidence of direct SRS-related complications. These patients were treated with repeat SRS (6.3%, n = 12), repeat resection (2.1%, n = 4), or both (3.2%, n = 6). For patients treated with a margin dose ≥ 16 Gy, the 2-, 4-, 6-, 8-, 10-, 12-, and 15-year actuarial progression-free survival rates are 100%, 100%, 95.7%, 95.7%, 95.7%, 95.7%, and 95.7%, respectively. Patients treated with a margin dose < 16 Gy, had 2-, 4-, 6-, 8-, 10-, 12-, and 15-year actuarial progression-free survival rates of 99.4%, 97.7%, 95.1%, 88.1%, 82.1%, 79.4%, and 79.4%, respectively. This difference was deemed statistically significant (p = 0.043). Reviewing the volumetric patient-specific measurements, the early follow-up volumetric measurements (at the 3-year follow-up) reliably predicted long-term volume changes and tumor volume control (at the 10-year follow-up) (p = 0.029).

CONCLUSIONS SRS is a durable and minimally invasive treatment modality for benign parasellar meningiomas. SRS offers high rates of growth control with a low incidence of neurological deficits compared with other treatment modalities for meningiomas in this region. Volumetric regression or stability during short-term follow-up of 3 years after SRS was shown to be predictive of long-term tumor control.

https://thejns.org/doi/abs/10.3171/2016.11.JNS161402

KEY WORDS meningioma; stereotactic radiosurgery; Gamma Knife
Meningiomas are one of the most common types of intracranial tumors and account for 24%–33% of primary brain tumors. The majority of meningiomas are WHO Grade I, thought to arise from arachnoidal cap cells, and are typically slow-growing, well-circumscribed lesions with benign histopathology.

A safe and complete resection, when feasible, constitutes a gold standard in the treatment of meningiomas. When feasible, resection of meningiomas, particularly for those located in the skull base or adjacent to critical neurovascular structures, remains an appealing benefit-risk ratio for SRS, with long-term tumor control rates of 92%–100% and acceptably low rates of associated morbidity and complications.

Methods

Patient Population

This is a retrospective analysis of a prospectively maintained database approved by the University of Virginia institutional review board. The database was assessed for patients who harbored a benign meningioma involving the sellar and/or parasellar region and were treated between 1986 and 2014 with a single-session SRS utilizing the Gamma Knife at the University of Virginia Health System.

SRS was performed as a primary upfront treatment for 44.4% (n = 84) of the patients, for a residual tumor after surgical debulking in 46.6% (n = 88) of patients, and for tumor recurrence (after complete resection) in 7.9% (n = 15) of patients. Of those patients who underwent a previously described SRS microsurgical resection, most (41.8%, n = 79) had undergone a single resection, although some (3.6%, n = 7) had undergone 3 or more attempts at microsurgical resection prior to SRS. The median interval between associated neurological symptoms and SRS was 11.5 months (range 0–290 months). The median tumor volume at the time of Gamma Knife radiosurgery (GKRS; Elekta, AB) was 5.6 cm³ (range 0.2–54.8 cm³). Volume was determined using the GammaPlan software (Elekta, AB) or the ImageJ software (National Institutes of Health) as previously described.

Radiosurgical Technique

The details of SRS (GKRS) performed at our center have been reported previously. The Leksell Gamma Knife Unit Model U was used from May 1989 to July 2001, followed by the use of the Model C from July 2001 to September 2007. The Gamma Knife Perfexion model...
was used after September 2007. The Kula software (Elekt, AB) was used for dose planning until June 1994, and then was replaced by GammaPlan software. The treating surgeon, in consultation with a medical physicist and radiation oncologist, devised the radiosurgical parameters and dose plans. Although there was some variation in the details of stereotactic imaging for radiosurgical planning varied over time, planning usually consisted of a pre- and postcontrast, volumetrically acquired gradient echo pulse sequences reconstructed into axial and coronal image stacks. Voxel sizes varied from 1 mm × 1 mm × 3 mm to 1 mm × 1 mm × 1.3 mm. When an MRI study could not be obtained because of medical contraindications (e.g., a cardiac pacemaker), a thin-slice (≤ 1.0 mm) stereotactic CT scan (with and without contrast) was obtained.

The median margin dose used in this cohort was 14 Gy (range 5–35 Gy). The majority of radiosurgical plans used margin doses lower than 16 Gy (82%, n = 155). The median maximum dose used was 32 Gy (range 12–70 Gy). The maximum dose distribution was roughly equal, with 49.7% (n = 94) of patients treated with a maximum dose equal to or higher than 32 Gy compared with 50.3% (n = 95) of patients treated with a margin dose lower than 32 Gy. The median isodose line used was 50% (range 21%–60%). Radiosurgical parameters are detailed in Table 1.

**Clinical and Radiological Assessment After GKRS**

After SRS, clinical examination was performed in all patients. Imaging follow-up occurred approximately 2 times a year in the first 2 years and then yearly thereafter. An attending neurosurgeon and neuroradiologist at the University of Virginia reviewed all neuroimages. Visible tumors were deemed to have had a stable response if the volumetry was within 10% of the original volume, to have increased in size if the volumetry was greater than 10% of the original volume, and to have decreased if it was at least 10% smaller than its original volume.48 Adverse radiation effects (AREs), were defined as any post-SRS perilesional hyperintensity noted on T2-weighted or FLAIR MRI sequences.

**Meningioma Volumetric Assessment**

The volumes of the parasellar meningiomas were determined for each imaging data set available for patients.
in a longitudinal fashion. The meningioma volume was determined from postcontrast T1-weighted images used for the SRS treatment plan. Volumes were computed by segmenting the meningioma on a slice-by-slice basis with numerical integration using the trapezoidal rule. The ImageJ software was used for contouring and volume computations.

**Statistical Analysis**

Statistical analysis was performed using a commercially available statistical package (version 20, IBM SPSS, IBM Corp.). Descriptive statistics were calculated for all variables, including mean, median, standard deviation, and frequency distributions as appropriate. Multivariate logistic regression was used to evaluate clinical covariates hypothesized to predict tumor control and post-GKRS improvement, including age, tumor volume at time of GKRS, sex, peritumoral edema, and tumor location. Kaplan-Meier analysis was performed for tumor control and post-GKRS improvement. All statistical tests were 2-sided unless described otherwise; p < 0.05 was considered statistically significant.

**Results**

**Tumor Control**

The specific tumor control parameters are detailed in Table 3. With a median follow-up time of 71 months (range 6–298 months), overall tumor volume control was achieved in 91.5% (n = 173) of patients. Of these, 48.1% (n = 91) showed tumor volume regression (volume decrease > 10%), and 43.4% (n = 82) showed tumor volume stability (volume change < 10%). At last follow-up, tumor progression was documented in 8.5% (n = 16) of patients. This figure was equally divided among infield recurrences (4.2%, n = 8) and out-of-field recurrences (4.2%, n = 8).

The overall 2-, 4-, 6-, 8-, 10-, 12-, and 15-year actuarial progression-free survival (PFS) rates were 99.5%, 98.1%, 95.2%, 89.6%, 84.8%, 82.5%, and 82.5%, respectively (Fig. 1). AREs were noted in 1.1% (n = 2). Radiation necrosis was not noted in this cohort. An example patient is presented in Fig. 2.

**Clinical and Neurological Outcome**

The most common post-SRS neurological symptoms were visual deterioration (11.6%, n = 22), followed by facial numbness (8.5%, n = 16), diplopia (8.3%, n = 15), and headache (7.4%, n = 14) (Table 2). All cases of visual deterioration occurred in patients with pre-SRS visual deficits. CN stability and improvement were logged together. Post-SRS, new or worsening CN deficits were observed in 54 instances (not patients, since a single patient may have developed multiple post-SRS CN deficits). Of these reports, 90.7% such instances (n = 49) were noted as secondary to tumor progression post-SRS and 9.3% were defined as a complication of SRS (all CNs). The most common post-SRS CN damaged was the trigeminal nerve (10.1%, n = 19), followed by the optic nerve (9.5%, n = 18) and the oculomotor nerve (4.8%, n = 9). Post-SRS pituitary hormone deficiency (any axis) was noted in 0.5% (n = 1) (Table 2).

### Table 3. Tumor outcomes, AREs, and further intervention

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. of Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor response*</td>
<td></td>
</tr>
<tr>
<td>Regression (vol decrease &gt;10%)</td>
<td>91 (48.1)</td>
</tr>
<tr>
<td>Stable (vol change &lt;10%)</td>
<td>82 (43.4)</td>
</tr>
<tr>
<td>Progression (vol increase &gt;10%)</td>
<td>16 (8.5)</td>
</tr>
<tr>
<td>Infield recurrence</td>
<td>8 (4.8)</td>
</tr>
<tr>
<td>Out-of-field recurrence</td>
<td>8 (4.2)</td>
</tr>
<tr>
<td>Radiation-induced changes</td>
<td></td>
</tr>
<tr>
<td>AREs</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Radiation necrosis</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Further intervention</td>
<td></td>
</tr>
<tr>
<td>Resection</td>
<td>10 (5.3)</td>
</tr>
<tr>
<td>Repeat GKRS</td>
<td>12 (6.3)</td>
</tr>
<tr>
<td>For the same tumor</td>
<td>4 (2.1)</td>
</tr>
<tr>
<td>For a different tumor</td>
<td>8 (4.2)</td>
</tr>
<tr>
<td>Observation</td>
<td>4 (2.1)</td>
</tr>
</tbody>
</table>

* Overall post-GKRS neurological improvement: 39.2% improved, 46.0% remained stable, and 14.8% deteriorated.
ing a median margin dose of 16 Gy (range 10–25 Gy). Of these 4 patients, 75% (n = 3) attained local tumor control after repeat SRS. One patient developed a new neurological deficit after repeat SRS. Repeat SRS for an out-of-field recurrence was performed in 4.2% (n = 8) additional patients, with a median tumor volume of 2.4 cm³ (range 1.2–5.8 cm³) during an interval time of 48 months (range 22–110 months), utilizing a median margin dose of 14 Gy (range 12–28 Gy). Of these 8 patients, 88% (n = 7) attained local tumor control after repeat SRS at last follow-up.

Post-SRS resection was performed in 5.3% (n = 10) of patients. This figure includes 2.1% (n = 4) patients who were treated only with post-SRS resection and 3.2% (n = 6) patients in whom repeat SRS failed as well. Histopathological examination of the resected tumor confirmed a WHO Grade I benign meningioma. A median tumor volume growth from 4.6 cm³ to 10.8 cm³ (82.8%) was noted during an interval time of 47 months (range 13–178 months). Of these 10 patients, 60% (n = 6) attained local tumor control after repeat SRS at last follow-up, 30% (n = 3) developed some new permanent neurological deficit after the resection, and 10% (n = 1) developed a new CN deficit (Table 4).

**TABLE 4. Treatment for recurrent/progressed parasellar meningioma**

<table>
<thead>
<tr>
<th>Further Treatment</th>
<th>At GKRS (cm³)</th>
<th>At Recurrence (cm³)</th>
<th>Increment (%)</th>
<th>Interval (mos)</th>
<th>Posttumor Control</th>
<th>Repeated Dose (Gy)</th>
<th>No. of New Post-GKRS Deficits</th>
<th>No. (%)</th>
<th>FU (mos)</th>
<th>Neurological CN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craniotomy (n = 10)</td>
<td>4.6 (1.2–16.8)</td>
<td>10.8 (1.7–36.6)</td>
<td>82.8 (11–1256)</td>
<td>47 (13–178)</td>
<td>6 (60)</td>
<td>NA</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infield recurrence (n = 4)</td>
<td>1.8 (1.2–28.5)</td>
<td>6.4 (1.6–32.1)</td>
<td>63.4 (40–400)</td>
<td>45 (25–132)</td>
<td>3 (75)</td>
<td>7.8</td>
<td>16 (10–25)</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outfield recurrence (n = 8)</td>
<td>7.7 (2.0–16.7)</td>
<td>2.4 (1.2–5.8)</td>
<td>56</td>
<td>48 (22–10)</td>
<td>7 (88)</td>
<td>14 (12–26)</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observation (n = 4)</td>
<td>5.6 (1.2–44.2)</td>
<td>7.8 (1.6–18.2)</td>
<td>30.1 (28–43)</td>
<td>21 (15–178)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FU** = follow-up; NA = not applicable.

Values are medians (range) unless indicated otherwise.

* Not the same tumor.
Pre-SRS Factors Influencing Tumor Progression

We evaluated factors related to tumor progression (i.e., tumor control) (Table 5 and Fig. 1). Tumor volume at the time of initial SRS was noted to influence the rate of local failure in both univariate and multivariate analyses, when grouped to lesions > 14 cm³ (HR 1.914 [95% CI 1.325–2.538], p = 0.044; and HR 1.832 [95% CI 1.134–2.594], p = 0.048, respectively).

A tumor margin dose lower than 16 Gy (HR 0.329 [95% CI 0.027–0.983], p = 0.043) was noted as predictive of tumor progression on multivariate analysis. As shown in Fig. 1, for patients treated with a margin dose ≥ 16 Gy, the 2-, 4-, 6-, 8-, 10-, 12-, and 15-year actuarial PFS rates are 100%, 100%, 95.7%, 95.7%, 95.7%, 95.7%, and 95.7%, respectively. Patients treated with a margin dose < 16 Gy, had 2-, 4-, 6-, 8-, 10-, 12-, and 15-year actuarial PFS rates of 99.4%, 97.7%, 95.1%, 88.1%, 82.1%, 79.4%, and 79.4%, respectively. This difference was deemed statistically significant (p = 0.043).

Tumor Volume Changes as a Predictor

Individual patient’s volumetric data are presented in Fig. 3. Patient’s tumor volume changes (relative to the 100% volume at the time of initial SRS) during the follow-up period are shown per patient. As depicted in Fig. 3, the median change in tumor volume manifests mean tumor volume control and regression. Reviewing the volumetric patient-specific measurements, an important role for early follow-up measurements arises. As depicted in Fig. 4, the early follow-up volumetric measurements (at the 3-year follow-up) reliably predicted long-term volume changes and tumor volume control (at the 10-year follow-up) (p = 0.029).

Discussion

Neurosurgeons face clinical challenges in the management of parasellar meningiomas. The difficulties these tumors present are related to the potential morbidity associated with the surgical approach, tumor exposure and dissection, their consistency (frequently firm) and vascularity, and their localization to critical neuroendocrine, vascular, and CN structures. These features usually taint surgical outcomes and make complete resection difficult. High reported rates of procedure-related morbidity and mortality, as well as high rates of delayed recurrence after partial resection, make resection a less appealing option. With increasing availability and reduced cost of imaging, these tumors are now being diagnosed at an earlier stage and smaller relative size, producing minimal symptoms. In these cases, the decision to undertake a potentially crippling surgery is even less appealing for both the patient and the surgeon.

Stereotactic Radiosurgery for Parasellar Meningiomas

With the addition of SRS to the armamentarium a few decades ago, aggressive resection and fractionated radiation therapy are less frequently considered for the treatment of parasellar meningiomas. Performing early SRS for smaller-volume tumors or subtotal resection followed by SRS (the so-called adoptive hybrid surgery) for larger-volume tumors that encroach on adjacent structures and cause a symptomatic mass effect has taken a central role. Authors of a recent meta-analysis of patients who had undergone treatment for cavernous sinus meningioma reported that surgical debulking followed by SRS resulted in better tumor control rates than surgery alone, regardless of extent of resection. In another study, the authors reported a significantly higher rate of cranial neuropathy for patients who had undergone resection higher than for patients who had undergone SRS alone.

Clinical and radiological evidence demonstrating that a lesion is a benign WHO Grade I meningioma leads to selection of SRS as the primary treatment modality. Spiegelmann et al. reported a cohort of radiologically diagnosed meningiomas treated with SRS, with a 98% tumor control rate. In their cohort of 219 patients with imaging-diagnosed meningiomas, a detailed history, clinical examination, and careful review of the neuroimaging studies, Flickinger et al. reported a 10-year actuarial misdiagnosis

| TABLE 5. Prognostic factors associated with local failure (Cox regression) |
|-----------------------------------------------|---------------------|---------------------|
| **Factors** | **Univariate** | **Multivariate** |
| | **p Value** | **HR*** | **95% CI** | **p Value** | **HR*** | **95% CI** |
| Age | 0.551 | 1.412 | 0.455–4.383 | 0.072 | 2.272 | 0.834–3.593 |
| Sex | 0.254 | 0.540 | 0.188–1.556 | 0.048 | 1.832 | 1.134–2.594 |
| Tumor vol (cm³) | 0.075 | | | | | |
| 4–14 | 0.060 | 1.833 | 0.995–2.729 | 0.043 | 1.329 | 0.027–0.983 |
| >14 | 0.044 | 1.914 | 1.325–2.538 | 0.048 | 1.832 | 1.134–2.594 |
| Margin dose† | 0.130 | 0.276 | 0.036–2.088 | 0.043 | 0.329 | 0.027–0.983 |
| Maximum dose | 0.940 | 1.038 | 0.386–2.794 | | | |
| Indication for GKRS | 0.930 | | | | | |
| Residual | 0.502 | 0.713 | 0.266–1.914 | | | |
| Recurrence | 0.987 | 0.000 | 0.000–0.000 | | | |
| Interval btwn symptoms & GKRS | 0.596 | 0.996 | 0.983–1.010 | | | |

Boldface type indicates statistical significance.

* Higher relative risk of local treatment failure.
† Margin dose segregated to ≥ 16 and < 16 Gy.
rate of 2.3% ± 1.4% and an actuarial tumor control rate of be 93.2% ± 2.7% at 10 years post-SRS. A multitude of reports from past decades did not find any differences in terms of tumor control or neurological outcomes between patients whose WHO Grade I meningioma diagnosis was confirmed with histological examination and those whose diagnosis was based on patients receiving a diagnosis via neuroimaging findings and clinical features alone.6–8,14,44

Table 6 summarizes important reported series of parasellar and other skull base meningiomas treated with single-session SRS, followed for long periods of time (up to 102.5 months). There is a wide range of long-term clinical outcomes after SRS for parasellar meningiomas in the available literature. Neurological improvement rates vary from 8% to 66%; reported post-SRS complication rates vary from 3% to 40%.10,12,13,18,23,27–29,34,51,56 Among published series with a cohort of 100 or more patients, rates of significant long-term complications (range 0%–16%) when the margin doses ranged from 12 to 15 Gy.10,12,13,18,27–29,34,56 Sughrue et al.54 reported pooled cranial neuropathy rates for patients undergoing microsurgical resection and SRS alone were 59.6% (95% CI 50.3%–67.5 and 25.7% (95% CI 11.5%–38.9%) (p < 0.05).44 In a multicenter study we reported that the risk of any new or worsening cranial neuropathy occurring after GKRS was 9.6%. We also found that the chance of improvement of pre-GKRS CN dysfunction after GKRS was 34%. New or progressive dysfunction after GKRS were most commonly found in CNs II and V.44 Of note, we reported SRS-induced optic nerve dysfunction in some patients in whom a maximum dose of 8 Gy or less (i.e., a “safe” dose) was delivered to the optic apparatus. Despite this low dose, some patients will experience visual decline.44 Overall, the data in Table 6 are in agreement with those of other treatment options and

![FIG. 3. Individual patient’s volumetric data. Changes (%) in tumor volume during the follow-up period are shown. The median change is depicted as a line with numeric values (100% refers to the tumor volume at the time of SRS), showing an overall tumor control. Refer to text. Figure is available in color online only.](image1)

![FIG. 4. The correlation between tumor volume changes (%) at 3 and 10 years post-SRS follow-up (FU). A strong linear correlation is shown (p = 0.029). Figure is available in color online only.](image2)
Radiosurgery for parasellar meningiomas, volumetric evaluation

J Neurosurg Volume 128 • February 2018

369

the natural history of parasellar meningioma, manifesting the appealing risk-to-benefit ratio offered by SRS for these challenging lesions.

CN dysfunction is most commonly seen in patients with parasellar or other skull base meningiomas treated with SRS. The most significant factor in CN deficit development was shown to be the length (volume) of the nerve irradiated, rather than the volume of tumor or the maximal dose. Tishler et al. noted that the maximum doses delivered to CNs were associated with neurological deficits in 29 patients after linear accelerator (LINAC) SRS and 33 patients after GKRS. Doses up to 40 Gy were shown to be safe for the CN in the parasellar region. In treating patients with parasellar and sellar tumor histologies, we have delivered doses of 20–30 Gy to the CNs in the parasellar region with only rare complications.

We report on a cohort of 189 patients harboring parasellar meningiomas that were treated with single-session SRS and monitored with clinical, radiographic, and volumetric measurements. We observed superior tumor control rates when parasellar meningiomas were treated with a margin dose of 16 Gy or more. Also, nearly half the tumors (48.1%) treated had regressed at last follow-up. Most importantly, the volumetric response of the tumor at 3
years after initial GKRS was predictive of the long-term response seen at 10 years. Thus, the SRS results appear durable, and a favorable response at 3 years is an early predictor of a durable and likely successful long-term outcome (Fig. 4). Nevertheless, we still recommend some degree of longitudinal follow-up in all meningioma patients, regardless of whether conservative management or some form of treatment (e.g., resection or SRS) is employed.

Study Limitations

The limitations of this study include those inherent to the nature of retrospective data analysis. Patients treated with upfront SRS by definition lacked a definitive tissue diagnosis of benign WHO Grade I meningioma. The parasellar region is sizeable, and its definition may differ somewhat among authors in terms of extent of tumor involvement. This region encompasses different discrete locations, each with a finite natural history and discrete responses to radiosurgery. In addition, patient selection bias may have affected the use of upfront radiosurgery, resection, radiation therapy, and salvage radiosurgery based on other medical social and patient related parameters. The validity may be limited by patient selection bias inherent to our treatment algorithms. Patients who developed post-radiosurgery complications were monitored more closely and had more frequent imaging and clinical evaluations, and thus might be overrepresented in this cohort. Comorbidities developing during the follow-up period may influence outcome parameters, which should be taken as a whole. The large cohort and long-term outcome, which contribute to the strength of analysis and statements serving as a major strength, also serve to increase heterogeneity of the cohort. The radiosurgical device, imaging, and software used are subject to change. From a procedural point of view, radiosurgical technology and treatment algorithms have been refined over the study period, and this could have contributed to a bias. However, despite these ongoing quality assurance and technical modifications, no significant difference in the outcome parameters over time was noted. Finally, the extent of generality of our results is not clear, and the results may reflect added experience seen at a tertiary center with appreciable SRS experience.

Conclusions

Stereotactic radiosurgery is a durable and minimally invasive option for the treatment of benign parasellar meningiomas. High rates of tumor control can be accomplished via SRS with an acceptably low incidence of neurological deficits and related neuropathies compared with other treatment modalities for meningiomas in this challenging region. Lesion volumetric regression or stability in relatively short-term follow-up of 3 years after SRS was shown to be predictive of long-term tumor control.

References
20. Hudgins WR, Barker JL, Schwartz DE, Nichols TD: Gamma
Radiosurgery for parasellar meningiomas, volumetric evaluation


Disclosures
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions
Conception and design: Cohen-Inbar, Sheehan. Acquisition of data: Cohen-Inbar, Tata, Moosa. Analysis and interpretation of data: Cohen-Inbar. Drafting the article: Cohen-Inbar. Critically revising the article: Cohen-Inbar, Tata, Moosa, Sheehan. Reviewed submitted version of manuscript: Cohen-Inbar, Lee, Sheehan. Approved the final version of the manuscript on behalf of all authors: Cohen-Inbar. Statistical analysis: Lee. Administrative/technical/material support: Sheehan. Study supervision: Sheehan.

Correspondence
Or Cohen-Inbar, Department of Neurological Surgery, University of Virginia Health System, Box 800212, Charlottesville, VA 22908. email: oc2f@virginia.edu.